{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026875","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2022-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.337563+00:00","generated_at":"2026-06-21T00:49:59.458301+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corbus shareholders approve reverse stock split at ratio up to 1:40","bullets":["Shareholders approved amendment to authorize reverse split from 1:4 to 1:40, board to set exact ratio.","Adjournment proposal also approved; both items passed at special meeting on Dec 20, 2022.","Record date for voting was Nov 7, 2022, with 125,280,881 common shares outstanding.","Final vote on reverse split: 25.79 trillion for, 5.06 trillion against, 0.47 trillion abstentions.","Reverse split intended to meet Nasdaq listing requirements and raise per-share price."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026875","json":"https://secwatch.observer/filing/0000950170-22-026875.json","markdown":"https://secwatch.observer/filing/0000950170-22-026875.md","text":"https://secwatch.observer/filing/0000950170-22-026875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022026875/0000950170-22-026875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022026875/crbp-20221220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:49:59.458301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8922d0fa2708ddf572f5ab01e7d082d58e1f7d9","claim":"Corbus Pharmaceuticals Holdings, Inc. shareholders approved Adoption and approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock at a ratio from 1:4 to 1:40 at the 2022-12-20 meeting.","evidence_excerpt":"1. The Reverse Stock Split Proposal. The votes were cast for this matter as follows: Votes For Votes Against Abstentions 25,794,110,289,993 5,064,240,621,803 474,524,757,330","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022026875/0000950170-22-026875-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-20"}],"fact_type":"shareholder_vote"},{"claim_id":"f5f666048a0658a6dba5ab2c50a09363020a6ee9","claim":"Corbus Pharmaceuticals Holdings, Inc. shareholders approved Approval of the adjournment of the Special Meeting to the extent there are insufficient votes to approve the Reverse Stock Split Proposal at the 2022-12-20 meeting.","evidence_excerpt":"2. The Adjournment Proposal. The votes were cast for this matter as follows: Votes For Votes Against Abstentions 51,281,428 10,784,629 603,069","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017022026875/0000950170-22-026875-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-20"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}